Edition:
United States

Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

37.88USD
23 Apr 2018
Change (% chg)

$-0.61 (-1.58%)
Prev Close
$38.49
Open
$38.49
Day's High
$38.61
Day's Low
$37.05
Volume
147,403
Avg. Vol
142,261
52-wk High
$41.80
52-wk Low
$14.06

Select another date:

Thu, Mar 8 2018

BRIEF-Audentes Therapeutics Q4 Loss Per Share ‍$0.82

* AUDENTES THERAPEUTICS REPORTS FOURTH QUARTER 2017 AND FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Wellington Management Group Llp Reports 10.85 pct Passive Stake In Audentes Therapeutics As Of Jan 31, 2018

* WELLINGTON MANAGEMENT GROUP LLP REPORTS 10.85 PERCENT PASSIVE STAKE IN AUDENTES THERAPEUTICS INC AS OF JANUARY 31, 2018 - SEC FILING‍​ Source text - (http://bit.ly/2nZykxi) Further company coverage:

BRIEF-Audentes Therapeutics Says Public Offering Of 5.75 Mln Shares Priced At $35/Share

* AUDENTES THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Audentes Therapeutics To Offer $150 Million Of Common Stock In Public Offering​

* AUDENTES THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Audentes Announces Positive Interim Data From First Dose Cohort Of Aspiro

* AUDENTES ANNOUNCES POSITIVE INTERIM DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY

BRIEF-Audentes Therapeutics Q3 ‍loss per share $ 0.88​

* Audentes Therapeutics reports third quarter 2017 financial results and provides corporate update

BRIEF-Audentes Therapeutics to release Q3 financial results Nov. 14

* Audentes Therapeutics to release third quarter 2017 financial results and provide corporate update on Tuesday, November 14, 2017 Source text for Eikon: Further company coverage:

Select another date: